

Serial No. 10/698,086
REPLY UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE

IN THE CLAIMS:

Claims 2-6, 8, 9, 11, 13, and 17-24 are cancelled without prejudice or disclaimer. Claims 1 and 12 have been amended herein without prejudice or disclaimer. All of the pending claims 1, 7, 10, 12, and 14-16 are presented. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of Claims:

1. (Currently amended) A method for determining whether a compound interferes with a phase in the life cycle of a virus other than an adenovirus, said method comprising the steps of:

- (a) providing a cell with infecting a PER.C6™ cell (represented by cells as deposited with the European Collection of Cell Cultures [ECACC] under accession number 96022940) with an essentially intact virus other than an adenovirus, said essentially intact virus comprising at least those elements of the virus sufficient for performing said phase in the virus' life cycle;
- (b) providing said PER.C6™ cell with the compound; and
- (c) determining whether said phase in the virus' life cycle is interfered with by the compound,

wherein step (a) and (b) may be performed simultaneously, or in any order, ~~and wherein said cell comprises a nucleic acid sequence encoding an adenovirus E1 early protein.~~

2.-6. (Canceled)

7. (Previously presented) The method according to claim 1, wherein said cell further comprises a nucleic acid sequence encoding an adenovirus E2 protein.

8. (Canceled)

Serial No. 10/698,086
REPLY UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE

9. (Canceled)

10. (Previously presented) The method according to claim 1, wherein determining whether the compound interferes with a phase in the life cycle of a virus comprises examining the virus' activity, the amount of the virus, the activity of a fragment of the virus, the amount of a fragment of the virus, or a mixture thereof.

11. (Canceled)

12. (Currently amended) A method for identifying a compound with antiviral activity, said method comprising the steps of:

- (a) ~~providing a cell with at least a fragment of a virus other than an adenovirus, said fragment infecting a PER.C6™ cell (represented by cells as deposited with the European Collection of Cell Cultures [ECACC] under accession number 96022940) with an essentially intact virus other than an adenovirus, said virus capable of performing able to perform a step in the life cycle of said virus;~~
- (b) providing said cell with a compound; and
- (c) determining whether said compound is ~~capable of influencing able to influence~~ said step in the life cycle of said virus,

wherein step (a) and (b) may be performed simultaneously, or in any order, ~~and wherein said cell comprises a nucleic acid sequence encoding an adenovirus E1 early protein.~~

13. (Canceled)

14. (Previously presented) The method according to claim 12, wherein said compound is part of a compound library.

Serial No. 10/698,086
REPLY UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE

15. (Previously presented) The method according to claim 12, wherein the method is performed in a high-throughput setting.

16. (Previously presented) The method according to claim 12, wherein said method further comprises the step of isolating said compound.

17.-24. (Canceled)